Hashan De Silva
Hashan was appointed to the Board of Directors in January 2023.
He is an experienced life sciences investment professional with extensive knowledge of the biotech, pharmaceutical and medical technology sectors. He worked as associate healthcare analyst at Macquarie Group covering ASX-listed healthcare companies and lead healthcare analyst at CLSA Australia before joining Karst Peak Capital in February 2021 as head of healthcare research. Prior to moving into life science investment Hashan worked at Eli Lilly in various roles focused on the commercialisation of new and existing pharmaceuticals.
He was educated at the University of New South Wales (Bachelor’s Degree in Medicine and Master’s Degree in Finance) and is a Chartered Financial Analyst.
Until December 2022 Hashan was Head of Healthcare Research at Karst Peak Capital Limited, a Hong Kong and Australian based specialist healthcare fund and is a non-executive director of Melbourne and Philadelphia based CurveBeam AI.